Synovio Therapeutics

Drug Candidate for Osteoarthritis Therapy

Startup

Synovio Therapeutics is a startup in the Health Tech & Life Sciences sector, established in 2025. Drug Candidate for Osteoarthritis Therapy. Synovio Therapeutics was founded by adi Sagiv Meister. Key investors include Israel Innovation Authority . The company has 1-10 employees.

The company follows a B2C business model. Product stage: R&D.

1
Rounds
1
Investors
1
Team
2025
Founded
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
At a Glance
Investors
Founders
Frequently Asked Questions
What does Synovio Therapeutics do?

Synovio Therapeutics develops a novel small molecule, Fenchone 1D, a specific agonist to the CB2 receptor as a drug candidate for Osteoarthritis therapy.

Who founded Synovio Therapeutics?

Synovio Therapeutics was founded in 2025 by adi Sagiv Meister (Founder).

What sector is Synovio Therapeutics in?

Synovio Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Where is Synovio Therapeutics located?

Synovio Therapeutics is based in Israel.

View Full Profile Classic View Website ↗